Business Context and Reporting Period
Company: Denali Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2021
Event: Regulation FD Disclosure regarding a strategic collaboration update.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
Collaboration Update: Takeda Pharmaceutical Company Limited exercised its option under an existing collaboration agreement with Denali Therapeutics.
Scope: The agreement now includes the co-development and co-commercialization of DNL593 (PTV:PGRN).
Therapeutic Area: DNL593 is an investigational, brain-penetrant progranulin replacement therapy intended for the potential treatment of frontotemporal dementia-granulin (FTD-GRN).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the option exercise but does not include specific forward-looking guidance, financial outlook, or risk factors within the text of this 8-K.
Legal Disclaimer: Information furnished in this Item 7.01 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial terms of the option exercise (e.g., milestone payments, equity stakes) in the attached press release (Exhibit 99.1).
- Review the full text of the existing collaboration agreement to understand the scope of co-development and co-commercialization rights.
- Confirm the current clinical development status of DNL593 (PTV:PGRN) for FTD-GRN.
- Assess the impact of this partnership on Denali's future cash burn and funding requirements.